Alimera Sciences Inc.'s IPO last week triggers the payment of a $15 million note plus interest to pSivida Corp.

pSivida Corp. (NSDQ:PSDV) reeled a $15.3 million payment from Alimera Sciences Inc. (NSDQ:ALIM) triggered by Alimera's April 21 initial public offering.
The two companies are collaborating on a drug-device combination called Iluvien, designed to treat diabetic macular edema. Last week Alimera raised $72 million in its IPO, selling 6.6 million shares at $11 each.
Concerns that the medical device tax will push companies to lay off workers and move operations...
The FDA clears OrthoSensor's Verasense device, designed to help surgeons fit knee replacement...
ArtVentive Medical Group wins CE Mark approval in the European Union for its EOS peripheral vascular...
The FDA hits Endologix's catheter introducer device recall with Class I status, its most serious...
A blogger's speculation that pSivida might be in line for a buyout bid sends the ophthalmology...